Biotron Limited
A.B.N. 60 086 399 144

BIOTRON RECEIVES ADDITIONAL A$208,463 TAX REFUND

Sydney, Australia – 23 October 2026 – Biotron Limited (ASX: BIT) ("Biotron" or "the Company") is pleased to announce it has received an amended income tax assessment from the Australian Taxation Office relating to the financial year ended 30 June 2024.

The amended assessment gives Biotron an additional refundable amount of $208,462.95. It increases the total tax offset refunds recognised for the FY2024 assessment from about $1.814 million to $2.022 million.

The additional refund provides further non-dilutive funding to the Company and strengthens Biotron's cash position as it progresses its priority development programs.

Biotron continues to focus its resources on advancing SedRx**,** including defining the regulatory and clinical development pathway for its next-generation general anaesthetic program, assessing the additional neurology opportunities, and evaluating the optimal development and partnering strategy for BIT-HBV001.

Chairman Dr Paul Kasian said: "The additional $208,000 refund is an excellent outcome for Biotron and provides further non-dilutive capital at an important point in the Company's development. The Board remains focused on disciplined capital allocation and directing available resources toward activities capable of delivering meaningful development and commercial value."

The amended assessment relates to the year ended 30 June 2024 and does not change Biotron's taxable income, which remains nil.

This announcement has been authorised for release by the Board of Biotron Limited.

FOR FURTHER INFORMATION

Marcelo Mora
Company Secretary
Biotron Limited
T: +61 2 9300 3344
E: mmora@miscorp.com.au
W: www.biotron.com.au

pjn13036

About Biotron Limited

Biotron Limited (ASX: BIT) is an Australian biotechnology company focused on developing and commercialising novel therapeutics across anaesthesia, neuroscience, and antiviral medicine. Its lead asset, SedRx, is a next-generation alfaxalone-based general anaesthetic supported by existing human clinical data and being advanced through regulatory planning for pivotal development, alongside evaluation of additional neuroscientific indications. Biotron also continues to develop BIT-HBV001, a novel antiviral candidate targeting Hepatitis B and Hepatitis Delta viruses, while pursuing partnering and commercialisation opportunities across its portfolio.